Robeco Institutional Asset Management B.V. Purchases 474,492 Shares of Edwards Lifesciences Corporation (NYSE:EW)

Robeco Institutional Asset Management B.V. boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 172.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 748,903 shares of the medical research company's stock after purchasing an additional 474,492 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.13% of Edwards Lifesciences worth $54,280,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Perigon Wealth Management LLC boosted its stake in Edwards Lifesciences by 6.9% during the first quarter. Perigon Wealth Management LLC now owns 4,325 shares of the medical research company's stock worth $313,000 after buying an additional 278 shares during the period. Alpine Bank Wealth Management bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth about $80,000. Golden State Wealth Management LLC boosted its stake in shares of Edwards Lifesciences by 125.0% during the 1st quarter. Golden State Wealth Management LLC now owns 5,135 shares of the medical research company's stock worth $372,000 after purchasing an additional 2,853 shares during the period. Lecap Asset Management Ltd. bought a new position in Edwards Lifesciences during the 1st quarter valued at about $2,909,000. Finally, Asset Management One Co. Ltd. grew its holdings in Edwards Lifesciences by 3.4% during the 1st quarter. Asset Management One Co. Ltd. now owns 250,089 shares of the medical research company's stock valued at $18,126,000 after purchasing an additional 8,271 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Wall Street Analyst Weigh In

EW has been the topic of a number of analyst reports. Piper Sandler upped their target price on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research note on Tuesday, May 13th. Robert W. Baird upped their price objective on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research report on Thursday, April 24th. Wall Street Zen lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Finally, Citigroup reiterated a "buy" rating and set a $95.00 price objective (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $80.20.

Edwards Lifesciences Trading Up 0.3%

Edwards Lifesciences stock opened at $77.19 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. The stock has a market cap of $45.28 billion, a PE ratio of 11.03, a price-to-earnings-growth ratio of 3.88 and a beta of 1.12. The stock has a 50-day moving average of $75.49 and a two-hundred day moving average of $73.12. Edwards Lifesciences Corporation has a one year low of $58.93 and a one year high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. Edwards Lifesciences's revenue was up 6.2% on a year-over-year basis. During the same period last year, the firm posted $0.66 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $69.81, for a total value of $663,195.00. Following the completion of the transaction, the vice president now owns 47,206 shares of the company's stock, valued at $3,295,450.86. The trade was a 16.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $74.40, for a total value of $837,000.00. Following the completion of the transaction, the chief financial officer now directly owns 41,098 shares of the company's stock, valued at $3,057,691.20. The trade was a 21.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,648 shares of company stock worth $2,998,866. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.